SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Sep 23, 2021 10:06 AM ET
Legal Newswire POWERED BY LAW.COM
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between December 27, 2018 and August 5, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before November 1, 2021.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Spectrum's manufacturing facility for ROLONTIS failed to maintain appropriate controls and procedures. These deficiencies diminished the likelihood of the Company's Biologics License Application (BLA) for ROLONTIS receiving FDA approval. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Spectrum, investors suffered damages.
The Schall Law Firm
Brian Schall, Esq.,
Contact Information:The Schall Law Firm
Brian Schall, Esq.,
Tags: Wire, Classaction-Marketing, Legal Newswire, United States, English